Martin CannonPresident and CEO
Mr. Cannon has served as President, CEO and board member of Hemanext since 2004. Prior to joining Hemanext, Mr. Cannon held senior positions with several leading management consulting firms including 15 years at Bain & Company and A.T. Kearney, which in 1997 acquired Cannon Associates, an international consulting and business development firm founded by Mr. Cannon. As a partner at Bain & Company and with his firm Cannon Associates, Mr. Cannon consulted extensively on growth and innovation strategies in a variety of industries including diagnostic instrumentation, blood banking and hospital management. Mr. Cannon also served as Executive Vice President with Commerce One, Inc., and Group President, Management Consulting with AppNet, Inc. where he was responsible for the development and deployment of software-based decision support platforms. He has served as a Board Member of the National Symphony Orchestra, The Washington Chorus and The US Russia Business Council. He is a graduate of Oxford University.
Joseph BarrettVice President General Counsel and Corporate Secretary
Mr. Barrett joined the company in 2016 with over 30 years’ experience in managing the legal affairs of medical device and specialty chemical companies. Prior to joining Hemanext, he spent 20 years at Baxter International where he managed the legal affairs of several of Baxter’s transfusion medicine businesses, including, Fenwal, Hemoglobin Therapeutics (Blood Substitutes), and Stem Cell Therapies. Prior to joining Baxter, he practiced law with the nationally recognized intellectual property law firm of Arnold, White and Durkee. He holds a B.S. in Pharmacy from the University of Oklahoma and a J.D. from the John Marshall Law School.
Vic DolecekVice President of Product Development and Operations
Mr. Dolecek joined the company in 2016 with over 30 years’ in medical device development and manufacturing. Prior to joining Hemanext, he spent 20 years at Cobe/Gambro/Terumo where he was the Director of Whole Blood R&D and Exploratory Projects. Ten years were spent with Medtronic CV and Spine Divisions developing cell washing systems and platelet gel systems. He holds a B.S. in Mechanical Engineering from the University of Colorado and has been awarded 50 US patents in the medical device field.
Andrew DunhamChief Scientific Officer
Dr. Dunham serves as Vice President of Research and Clinical Affairs since January 2015. Prior to joining Hemanext, Dr. Dunham held researcher and senior positions at both specialty chemical and healthcare companies including 14 years at Baxter Healthcare. His experience at Baxter included leading the corporate R&D group comprising the global centers for Sterility Assurance, Particle & Imaging, Human Factors & Industrial Design, Pre-clinical, Toxicology, and Histology, Biochemistry and Cell Biology, Organic Synthesis and Analytical Chemistry, Advanced Engineering and Prototyping, and Stability Operations teams. Dr. Dunham has extensive experience applying this broad range of technologies across a diverse range of pharmaceutical and medical device products from development through product support. He is a graduate of the Northern Illinois University, the University of Colorado at Boulder, and had post-doctoral research experience at the University of Colorado Health Sciences Center School of Pharmacy.
Lynn MallettChief Financial Officer
Ms. Mallett joined the organization in September 2017 as CFO and brings 20 years of finance and accounting experience to NHSi. Prior to joining Hemanext, Ms. Mallett was a finance executive at Baxalta, Inc, following its spin-out from Baxter International in July 2015, where she provided finance leadership to both the global Biosimilars Commercial Team and the global R&D Function. Before that, Ms. Mallett held various finance positions at various organizations including Pfizer, Inc., NxStage Medical, Inc., Serono and Haemonetics. Lynn earned both her M.S. in Management and B.S. in Business Administration from Eastern Nazarene College.
Tony PareChief Commercial Officer
Tony has 30+ years experience in general management and business development, with a track record of executing large scale, value creation strategies and improving profitability. Recently, Tony was the VP of Business Development, Mergers and Acquisitions for Haemonetics Corporation. In this role, Tony was responsible for all inorganic growth activity, as well as strategy development for entering into new markets. Tony led the acquisition and integration of 13 companies that represented over $300M of the $930M in corporate revenues. In a prior role, Tony started and led the blood software franchise as its President and General Manager, and grew it to $70M in revenues. Tony holds a B.S. in Engineering from Maine Maritime Academy and a Masters in Engineering Administration from George Washington University.